Lexaria Bioscience Corp. (LEXX): Revenue
$705.9K
Year ended 2025-08-31
$194.0K
Trailing 12 months to 2026-05-31
+40.3%
3-year compound annual growth
+17.5%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-08-31 | $705.9K | +52.0% | 2025-11-28, From 2024-09-01 |
| 2024-08-31 | $464.3K | +105.2% | 2025-11-28, From 2023-09-01 |
| 2023-08-31 | $226.2K | -11.4% | 2024-11-26, From 2022-09-01 |
| 2022-08-31 | $255.4K | -64.7% | 2023-11-20, From 2021-09-01 |
| 2021-08-31 | $722.7K | +129.6% | 2022-11-28, From 2020-09-01 |
| 2020-08-31 | $314.8K | n/a | 2021-11-29, From 2019-09-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $705.9K | +52.0% |
| Polomar Health Services, Inc. (PMHS) | 2025-12-31 | $648.2K | n/m |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $642.0K | -71.7% |
| Hyperion Defi, Inc. (HYPD) | 2025-12-31 | $813.5K | n/m |
| Onconetix, Inc. (ONCO) | 2025-12-31 | $815.4K | -67.7% |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $601.0K | +5.4% |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $590.1K | n/a |
| Rallybio Corp (RLYB) | 2025-12-31 | $858.0K | +34.9% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $570.0K | +13.8% |
Compare LEXX, PMHS, BTAIQ, HYPD side by side · Screen every company in Pharmaceutical Preparations ↗